QIAGEN N.V. (QGEN) recently secured FDA clearance for the QIAstat-Dx Respiratory Panel Plus syndromic test. Previously authorized under the FDA Emergency Use Authorization (“EUA”) as the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the test is designed to support clinical decision-making in diagnosing upper respiratory infections and covers 21 viral and bacterial targets. The latest development will strongly boost the company’s Molecular Diagnostics business. Significance of the QIAstat-Dx Respiratory Panel Plu ...